BIAF missed EPS expectations by 72.11%
Nov 16, 2025, 11:39 AM
0.00%
What does BIAF do
bioAffinity Technologies, based in San Antonio, Texas, focuses on non-invasive early-stage cancer diagnosis and treatment, employing 75 staff since its IPO on August 26, 2022. Its first product, CyPath Lung, aids in detecting early-stage lung cancer, enhancing patient intervention decisions.
BioAffinity Technologies (BIAF) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, BioAffinity Technologies's actual EPS was -$4.74, missing the estimate of -$2.75 per share, resulting in a -72.11% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.